Brief: Inhibikase Therapeutics Completes Enrollment Of Phase 2 Trial Evaluating Risvodetinib In Untreated Parkinson’S Disease
17/06/2024 13:40
June 17 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS COMPLETES ENROLLMENT OF THE PHASE
2
‘201’ TRIAL EVALUATING RISVODETINIB IN UNTREATED PARKINSON’S
DISEASE
* INHIBIKASE THERAPEUTICS INC: EXPECTS TO REPORT TRIAL
RESULTS IN
Q4 OF 2024
Source text for Eikon: ID:nGNX6gD1DP
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary